AI-Powered Psychedelic Treatments: Special Status And Next-Gen Contests Winners
As psychedelics and AI travel their own development paths, here are some initiatives looking at ways of enhancing the former with the latter’s help.
MA, FL And OH Psychedelics Scientists And Educators’ Latest Research And Views
Along with a growing scientific corpus supporting the therapeutic potential of psychedelics, several states and most noticeably Massachusetts are seeing the decriminalization of natural substances via local measures.
Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More
Major Investor Commits $30 Million To Psychedelics Funding
Lucy Scientific Goes After Pasithea Therapeutics Common Shares For A ‘142% Premium’ Deal
Health Canada-licensed psychedelics producer Lucy Scientific Discovery (NASDAQ: LSDI) announced it has sent a proposal to biotech business Pasithea Therapeutics Corp.
Disney, Amgen, First Republic, Psychedelics: How One CEO’s Universal Deal-Making Approach Shapes Industries
In the dynamic world of business, adaptability is king, a principle veteran executive Richard Nanula has embodied throughout his career. "Every place I've been... maybe you could conclude that they might not fit because one of them didn't have much relation to the other.
Numinus’ Clinical Arm To Lead Enrollment Site For MindMed’s Phase 2b LSD Study
Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b stud
DMT’s Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up
Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous (IV) formulation of the company’s DMT compound, AP-188, aiming to treat both stroke and Traumati
Why A National Cannabis Organization Sacked Half Its Staff, CEO Turnovers And More Exec Changes
NCIA Sacks Half Of Its Team To Increase Financial Strength
Reunion Neuroscience Announces $13.1M Take-Private Transaction With Biotech Investment Firm
As of May 31, clinical-stage psychedelics company Reunion Neuroscience Inc.
Major Investor Commits $30M To Psychedelics Funding
Canadian psychedelics biotech Cybin Inc. (NYSE: CYBN) entered into a common share purchase agreement with institutional investor Lincoln Park Capital Fund (LPC) for the sale of up to $30 million (CA$41) of its common shares within a 36-month period.